Mecp2 Knockout cell line (NIH/3T3)
Catalog Number: KO01486
Price: Online Inquiry
Catalog Number: KO01486
Price: Online Inquiry
Product Information | |
---|---|
Product Name | Mecp2 Knockout cell line (NIH/3T3) |
specification | 1*10^6 |
Storage and transportation | Dry ice preservation/T25 live cell transportation. |
species | Mouse |
Gene | Mecp2 |
Gene ID | 17257 |
Build method | Electric rotation method / virus method |
Mycoplasma testing | Negative |
Parental Cell Line | NIH/3T3 |
Quality Control | Genotype: Mecp2 Knockout cell line (NIH/3T3) >95% viability before freezing. All cells were tested and found to be free of bacterial, viruses,mycoplasma and other toxins. |
Gene Information | |
---|---|
Gene Official Full Name | methyl CpG binding protein 2provided by MGI |
Also known as | Mbd5; WBP10; 1500041B07Rik; D630021H01Rik |
Gene Description | Enables several functions, including histone reader activity; nucleic acid binding activity; and promoter-specific chromatin binding activity. Involved in several processes, including associative learning; negative regulation of smooth muscle cell differentiation; and negative regulation of transcription by RNA polymerase II. Acts upstream of or within several processes, including learning or memory; nervous system development; and regulation of gene expression. Located in cytosol; heterochromatin; and nucleus. Is expressed in several structures, including alimentary system; early conceptus; nervous system; paraxial mesenchyme; and sensory organ. Used to study Rett syndrome. Human ortholog(s) of this gene implicated in Rett syndrome; autistic disorder; gastrointestinal system disease; severe congenital encephalopathy due to MECP2 mutation; and syndromic X-linked intellectual disability (multiple). Orthologous to human MECP2 (methyl-CpG binding protein 2). [provided by Alliance of Genome Resources, Apr 2025] |
Expression | Ubiquitous expression in whole brain E14.5 (RPKM 8.6), CNS E18 (RPKM 7.6) and 26 other tissues See more |
We develop gene knockout solutions tailored to customer requirements and the condition of the target gene.
Cas9 Protein
Cas9 mRNA sgRNA
Cas9 Plasmid
Cas9 Virus
A – Exon KO
gRNAs are designed in the introns flanking the exon, targeting non-multiple-of-3 base deletions in the exon, resulting in frameshift mutations.
B - Frameshift KO
gRNAs are designed within the exon, creating non-multiple-of-3 base deletions to induce frameshift mutations.
C - Complete KO
The entire gene coding sequence is deleted, achieving large-scale knockout effects.
KO Strategy Design
CRISPR Plasmid/Lentiviral Vector Construction
Lentiviral Packaging
Cell Transfection/Lentiviral Infection
Drug Selection
Cell Cryopreservation
Quality Control
Sequencing Validation
Monoclonal Cell Line Generation
Pool Efficiency Validation
Please note that all services are for research use only. Not intended for any clinical use.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.